Neuraxis secures $3 million financing

Carmel, ind., nov. 14, 2023 (globe newswire) -- neuraxis, inc. (“neuraxis,” or the “company”) (nyse american: nrxs), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced it has secured a $3 million financing for neuraxis through a preferred stock offering priced at $2.38 per share.
NRXS Ratings Summary
NRXS Quant Ranking